| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| April 23, 2026 | ±2.4% | +12.9% | under-priced |
| October 23, 2025 | ±2.5% | +10.9% | under-priced |
| July 24, 2025 | ±4.0% | +22.8% | under-priced |
| April 24, 2025 | ±4.5% | -3.5% | over-priced |
| October 24, 2024 | ±2.1% | +15.4% | under-priced |
| July 25, 2024 | ±3.3% | -14.4% | under-priced |
| April 25, 2024 | ±2.6% | -4.5% | under-priced |
| October 26, 2023 | ±3.1% | -8.6% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $1.92 | $845M | $139M |
| Q4 FY2025 | $1.82 | $805M | $132M |
| Q3 FY2025 | $1.92 | $805M | $140M |
| Q2 FY2025 | $1.82 | $767M | $132M |
West Pharmaceutical Services, Inc. (WST) reports in 85 days, with the next report estimated for September 6, 2026. Across the last 8 reports, options priced an average ±3.1% earnings move while the stock actually moved 11.6% on average — the market has tended to under-price WST's earnings risk. Fundamentals into the print: EPS up 56.1% year-over-year, revenue up 21.0%. QuantLogix's live 5-factor engine currently reads WST as a buy at 59/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →